• Home
  • NEW DAY MEDICINE
  • 5 (67) 2024
  • 55 -5 (67) 2024 - Rakhimov N.M., Tulanov B.T. - THE IMPORTANCE OF PALLIATIVE CARE FOR ANOREXIA-CACHEXIA SYNDROME IN ADVANCED BREAST CANCER

55 -5 (67) 2024 - Rakhimov N.M., Tulanov B.T. - THE IMPORTANCE OF PALLIATIVE CARE FOR ANOREXIA-CACHEXIA SYNDROME IN ADVANCED BREAST CANCER

THE IMPORTANCE OF PALLIATIVE CARE FOR ANOREXIA-CACHEXIA SYNDROME IN ADVANCED BREAST CANCER

Rakhimov N.M. - Samarkand State Medical University Uzbekistan

Tulanov B.T. - Kashkadarya regional branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology

Shakhanova Sh.Sh. - Samarkand State Medical University Uzbekistan

Resume

The factors leading to the occurrence of anorexia-cachexia syndrome are considered multifactorial and are expressed in an increasing decrease in body weight, a decrease in muscle and adipose tissue. Eating disorders lead to an imbalance of metabolic processes in my body, a violation of protein and energy metabolism. This process manifests itself in the form of an increasing deterioration in the general condition of my body. Of the factors that cause anorexia-cachexia syndrome in cancer, strictly speaking, it is an important factor determining the survival and quality of life of patients.

Keywords: diffuse breast cancer, anorexia-cachexia syndrome, palliative care.

First page

322

Last page

329

For citation: Rakhimov N.M., Tulanov B.T., Shakhanova Sh.Sh. - THE IMPORTANCE OF PALLIATIVE CARE FOR ANOREXIA-CACHEXIA SYNDROME IN ADVANCED BREAST CANCER //New Day in Medicine 5(67)2024 322-329 https://newdayworldmedicine.com/en/article/3758

List of References

  1. Muscaritoli, M., Corsaro, E., and Molfino, A. (2021). Awareness of Cancer-Related Malnutrition and Its Management: Analysis of the Results from a survey conducted among medical oncologists. Frontiers in oncology, 11, 682999.
  2. Hébuterne, X., Lemarié, E., Michallet, M., de Montreuil, C. B., et al. (2014). Prevalence of malnutrition and current use of nutrition support in patients with cancer. Journal of parenteral and enteral nutrition, 38(2), 196–204.
  3. Wiegert, E., de Oliveira, L. C., Calixto-Lima, L., Mota E Silva Lopes, M., and Peres, W. (2020). Cancer cachexia: Comparing diagnostic criteria in patients with incurable cancer. Nutrition (Burbank, Los Angeles County, Calif.), 79-80, 110945.
  4. Ezeoke, C. C., Morley, J. E. (2015). Pathophysiology of anorexia in the cancer cachexia syndrome. Journal of cachexia, sarcopenia and muscle, 6(4), 287–302.
  5. Asakawa A, Fujimiya M, Niijima A, Fujino K, Kodama N, et al. (2010) Parathyroid hormone-related protein has an anorexigenic activity via activation of hypothalamic urocortins 2 and 3. Psychoneuroendocrinology; 35:1178–1186.
  6. Lloyd RB, Nemeroff CB (2011). The role of corticotropin-releasing hormone in the pathophysiology of depression: Therapeutic implications. Curr Top Med Chem; 11:609–617.
  7. Imai H, Soeda H, Komine K, Otsuka K, Shibata H. (2013) Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancer. BMC Palliat Care; 12:38.
  8. Muscaritoli, M., Arends, J., and Aapro, M. (2019). From guidelines to clinical practice: a roadmap for oncologists for nutrition therapy for cancer patients. Therapeutic advances in medical oncology, 11, 1-14.
  9. Cederholm T, Barazzoni R, Austin P, et al. (2017). ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr; 36: 49–64.
  10. Mendes NP, Barros TA, Rosa COB, et al. ( 2019). Nutritional screening tools used and validated for cancer patients: a systematic review. Nutr Cancer; 71: 898–907.
  11. Du H, Liu B, Xie Y, et al. (2017) Comparison of different methods for nutrition assessment in patients with tumors. Oncol Lett ; 14: 165–170.
  12. Advani, S M, Advani, P G, VonVille, H M, and Jafri, S H. (2018). Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials. BMC cancer, 18(1), 1174.
  13. Bai Y, Hu Y, Zhao Y, et al. (2017) Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. Support Care Cancer; 25:1651–9.
  14. Nishie K, Yamamoto S, Nagata C, et al. (2017) Anamorelin for advanced non-small cell lung cancer with cachexia: systematic review and meta-analysis. Lung Cancer; 112:25–34.
  15. Garcia JM, Boccia RV, Graham CD, et al.(2015) Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol.; 16:108–16.
  16. Turcott JG, Núñez MRG, Flores-Estrada D, et al. (2018) The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer.; 26:3029.
  17. Bar-Sela, G, Zalman, D, Semenysty, V, and Ballan, E. (2019). The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study. Integrative cancer therapies, 18.
  18. Del Fabbro E, Dev R, Hui D, et al. (2013). Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol; 31:1271–6.
  19. Jatoi A, Ritter HL, Dueck A, et al. (2010) A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer.; 68:234–9.
  20. Yennurajalingam S, Willey JS, Palmer JL, et al. (2012) The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. J Palliat Med.; 15:1059–64.

    file

    download